AbbVie’s effort to protect Humira’s market share is getting expensive. On Friday, the company announced a 40% decline in the megablockbuster drug’s US sales for the first quarter. While it managed to hang onto the vast majority of market share, AbbVie did so by offering substantial discounts to compete with the biosimilars that have flooded … Continue reading AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused